

silenceworks

Milestones in our progress to the clinic with **ddRNAi**

Benitec Biopharma continues to make progress towards our key goal - clinical validation of our transformational gene silencing technology.

Below we summarise our recent promotion, research, licensing and capital-raising activities that are increasing awareness of Benitec's programs and positioning the company for success.

We're pleased with progress and are looking to the future with great confidence.

Gaining positive feedback on Hepatitis C from the NIH

June 12, 2013

The National Institutes of Health (NIH) Recombinant DNA Advisory Committee provided a very **favourable review** of the clinical trial protocol for TT-034, our Hepatitis C therapeutic. This is a significant milestone in TT-034's progress to the clinic; the next key milestone will be filing an Investigational New Drug (IND) application with the US FDA. **TT-034** is a major focus for the company.

Securing capital to advance key programs

July 2013

Benitec secured over A\$10 million in a recent capital raise to progress two of our most advanced programs, TT-034 for **Hepatitis C** and Tribetarna™ for **NSCLC** (Non-Small Cell Lung Cancer). The capital, raised via a **Private Placement** (A\$7.9m) and a **Share Purchase Plan** (A\$2.84m), demonstrated continued confidence in the company's programs and direction.

Presenting at two major international conferences

August 2013

Benitec's TT-034 program for Hepatitis C has been chosen for oral presentation at the November conference of the pre-eminent **American Association for the Study of Liver Disorders** (AASLD) in Washington, and at the prestigious **International Symposium on Hepatitis C Virus and Related Viruses** (HCV 2013) in Melbourne in October. This indicates a growing international interest in Benitec's unique approach to Hepatitis C therapy.

Advancing lung cancer treatment towards the clinic

August 8, 2013

The University of NSW has granted Benitec exclusive rights to advance our collaborative Tribetarna™ program with **The Children's Cancer Institute Australia** (CCIA) for NSCLC (Non-Small Cell Lung Cancer). Benitec and CCIA now plan to commence toxicity testing in preparation for clinical trial entry, and to develop a diagnostic to identify the most appropriate NSCLC patients for the trial.

Extending ddRNAi to cancer vaccines

August 6, 2013

Benitec has exclusively licensed ddRNAi to US-based **Regen Biopharma** to develop cancer vaccines based on silencing 2,3 Indoleamine 2,3-Dioxygenase in dendritic cells. This innovative, non-toxic approach to treat cancer underscores the wide application of Benitec's novel technology.

Showcasing ddRNAi at Bioshares Biotech Summit

July 19-20, 2013

CEO, Dr Peter French, showcased Benitec's research in a **presentation** to this **annual summit** held in Queenstown (New Zealand) this year. Our presentation, which was in the segment '**Lands of Opportunity**' focusing on companies and technologies with large global opportunities, reinforced the potential of ddRNAi to the audience of fund managers, retail investors and industry groups.

Gaining positive feedback from a key market analyst

August 12, 2013

Lodge Partners summed up Benitec's recent progress, comparing it favourably with several much larger, more highly-capitalised RNAi companies. Lodge's analyst concluded that Benitec was comparatively 'undervalued' and retained its 'buy' recommendation.